Table 3.

Relationship between expression levels of DDX60 and clinical indicators.

	Training data (n = 350)				Validation data (n = 350)
	High	Low	X 2	p values	High	Low	X 2	p values
Radiotherapy			0.185	0.667			1.548	0.214
Yes	100	95			113	97
No	75	80			65	75
Age			0.561	0.454			0.175	0.675
≥60	79	87			84	86
<60	96	88			94	86
History of other malignancies			0.000	1.000			0.084	0.772
Yes	7	7			10	12
No	168	168			167	160
Histologic type			1.467	0.480			2.829	0.243
IDC	122	110			116	113
MBC	12	16			21	12
ILC	39	44			38	44
First surgical procedure			0.701	0.873			1.211	0.750
Lumpectomy	40	43			40	42
Modified radical
Mastectomy	58	62			59	53
Others	33	31			25	31
A simple mastectomy	34	29			40	36
T stage			1.091	0.296			0.186	0.666
T3/T4	24	32			27	30
T1/T2	151	142			151	142
N stage			0.675	0.411			0.156	0.693
N2/N3	34	27			36	30
N0/N1	140	146			141	136
M stage			0.070	0.791			0.002	0.963
M1	5	3			1	2
M0	154	146			153	144
ER status by IHC			0.197	0.657			0.867	0.352
Positive	133	138			138	128
Negative	34	30			27	34
PR status by IHC			0.041	0.840			3.496	0.062
Positive	118	116			126	107
Negative	49	52			38	53
HER2 status by IHC			2.748	0.253			2.706	0.259
Positive	42	30			38	25
Overexpression	24	27			20	20
Negative	82	92			93	99
Chemotherapy			4.228	0.040			0.537	0.464
Yes	155	140			156	146
No	20	35			21	26

Note. Abbreviations are the same as in Table 1.